Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

For children ages 12 to 17, an adult should supervise the shots. Dupixent's list of uses already includes asthma, eczema, chronic sinus inflammation with nasal polyps, eosinophilic food pipe ...

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic. Dupixent (dupilumab) – an ...

President and Chief Executive Officer at the Asthma ... approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as Dupixent for ...

such as atopic dermatitis and asthma — providing patients with one treatment that might help multiple atopy conditions.” Approval of (Dupixent, Regeneron/Sanofi) was based on data from two ...